| Moderna is a biotechnology company focusing on messenger RNA (mRNA) therapeutics and vaccines to create medicines. mRNA medicines are designed to direct the body's cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a range of diseases. Co. is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, autoimmune diseases and cardiovascular diseases. Co. has a collaboration agreement with the Institute of Life Changing Medicines to develop a mRNA therapeutic (mRNA-3351) for Crigler-Najjar Syndrome Type 1. We show 17 historical shares outstanding datapoints in our MRNA shares outstanding history coverage, used to compute MRNA market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing MRNA market cap history over the course of time is important for investors
interested in comparing MRNA's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of MRNA versus a peer is one thing; comparing
MRNA market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like MRNA can fluctuate over the course of history.
With this page we aim to empower investors researching MRNA by allowing them to research the MRNA market cap history.